Enhancing Shiga toxin detection using surface plasmon resonance a study of antibody immobilization strategies., PMID:40379791
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)., PMID:40332560
Isolation of Shiga toxin-producing Escherichia coli O157 and non-O157 from retail imported frozen beef marketed in Saudi Arabia using immunomagnetic separation and multiplex PCR., PMID:40271089
Inhibition of tumour necrosis factor alpha by Etanercept attenuates Shiga toxin-induced brain pathology., PMID:39920757
Monocytes serve as Shiga toxin carriers during the development of hemolytic uremic syndrome., PMID:39871175
Ultrasensitive "Hunter of Target": Rabbit Monoclonal Antibody-Based Competitive Lateral Flow Immunoassay for Saxitoxin., PMID:39787431
Serogroups and Toxin Variants of Clinical Shiga Toxin-Producing Escherichia coli Strains Isolated from Patients with Hemolytic Uremic Syndrome in Turkey., PMID:39728667
Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial., PMID:39692817
A novel multiplex and glycoprotein-based immunochromatographic serologic IgM test for the rapid diagnosis of Escherichia coli O157 and O145 causing bloody diarrhea and hemolytic uremic syndrome., PMID:39480070
An anti-Shiga toxin VHH nanobody multimer protects mice against fatal toxicosis when administered intramuscularly as repRNA., PMID:39392311
Detection of Shiga toxin-producing Escherichia coli in dairy cows: genetic characterization and inhibition of adherence by cattle anti-STEC antibodies to HEp-2 cell., PMID:39331343
Development of a Quick and Highly Sensitive Amplified Luminescent Proximity Homogeneous Assay for Detection of Saxitoxin in Shellfish., PMID:39195751
Nanoflower Microreactor Based Versatile Enhancer for Recognition Cofactor-Dependent Enzyme Biocatalysis toward Saxitoxin Detection., PMID:39167418
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study., PMID:39061413
Steroid sulfatase in mouse liver and testis: Characterization, ontogeny and localization., PMID:39053631
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world., PMID:38777579
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study., PMID:38451463
The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectiveness., PMID:38424386
Production of egg yolk antibody (IgY) against a chimeric protein containing IpaD, StxB, and TolC antigens from Shigella: An investigation of its prophylactic effects against Shiga toxin (Stx) and Shigella dysenteriae in vitro and in vivo., PMID:38404796
Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study., PMID:38342785
Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)., PMID:38329615
Development of an indirect ELISA system for diagnosis of porcine edema disease using recombinant modified Stx2e antigen., PMID:38285612
Eculizumab in severe Shiga toxin-mediated haemolytic uraemic syndrome., PMID:38238162
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study., PMID:38231271
Identification of the glycopeptide epitope recognized by a protective Cryptosporidium monoclonal antibody., PMID:37725059
Nanograms of SARS-CoV-2 spike protein delivered by exosomes induce potent neutralization of both delta and omicron variants., PMID:37607200
Nasal immunization with H7 flagellin protects mice against hemolytic uremic syndrome secondary to Escherichia coli O157:H7 gastrointestinal infection., PMID:37260706
Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins., PMID:37093009
Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter Prospective Observational Study., PMID:37072224
Shiga Toxin (Stx) Type 1a and Stx2a Translocate through a Three-Layer Intestinal Model., PMID:36977098
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study., PMID:36949388
Endotoxin-Free Stx2B-C-CPE Vaccine and Its Optimized Adjuvant Regimen for Preventing Food Poisoning., PMID:36722281
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients., PMID:36316648
Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment., PMID:36288859
Immunogenicity of inactivated Escherichia coli O157:H7 with Stx2B microparticle in mice., PMID:36246065
Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment., PMID:36205100
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study., PMID:36097739
A novel shiga based immunotoxin against Fn-14 receptor on colorectal and lung cancer., PMID:35978517
Neutrophil Extracellular Traps Induced by Shiga Toxin and Lipopolysaccharide-Treated Platelets Exacerbate Endothelial Cell Damage., PMID:35811684
Etiological diagnosis of post-diarrheal hemolytic uremic syndrome (HUS): humoral response contribution., PMID:35802271
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience., PMID:35763113
Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)., PMID:35397503
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study., PMID:35305579
Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives., PMID:35223548
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men., PMID:34975732
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study., PMID:34922444
The Deleterious Effects of Shiga Toxin Type 2 Are Neutralized In Vitro by FabF8:Stx2 Recombinant Monoclonal Antibody., PMID:34822608
Development of a homogeneous time-resolved FRET (HTRF) assay for the quantification of Shiga toxin 2 produced by E. coli., PMID:34395095
The interactions of bacteriophage Ace and Shiga toxin-producing Escherichia coli during biocontrol., PMID:34329454
Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing Escherichia coli., PMID:34268129
For research use only. Not for human or drug use.
